Fragment screening of cyclin G-associated kinase by weak affinity chromatography

Analytical and Bioanalytical Chemistry

Volumn 404, Issue 8, 2012, Pages 2417-2425

  Meiby, Elinor ^a   Knapp, Stefan ^b   Elkins, Jonathan M ^b   Ohlson, Sten ^a  

^a LINNAEUS UNIVERSITY   (Sweden)

^b UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

Cyclin G associated kinase; Fragment screening; Fragment based drug discovery; Weak affinity chromatography

Indexed keywords

AFFINITY INTERACTIONS; ATP-BINDING SITE; CAPILLARY HPLC; CHIRAL CENTERS; CHIRAL SCREENING; CYCLIN G-ASSOCIATED KINASE; DISSOCIATION CONSTANT; DRUG DISCOVERY; DRUG TARGETS; FRONTAL AFFINITY CHROMATOGRAPHIES; MS DETECTION; SCREENING METHODS; SELECTIVE RETENTION; SMALL MOLECULES; VIRTUAL SCREENING;

AFFINITY CHROMATOGRAPHY; DIGITAL LIBRARIES; DISSOCIATION; LEAD COMPOUNDS; MASS SPECTROMETRY; PROTEINS; STEREOCHEMISTRY;

ENZYMES;

CYCLIC GMP DEPENDENT PROTEIN KINASE; CYCLIN G; PEPTIDE FRAGMENT;

AFFINITY CHROMATOGRAPHY; ARTICLE; CHEMICAL STRUCTURE; MASS SPECTROMETRY; METABOLISM; MOLECULAR LIBRARY; STANDARD; STEREOISOMERISM;

CHROMATOGRAPHY, AFFINITY; CYCLIC GMP-DEPENDENT PROTEIN KINASES; CYCLIN G; MASS SPECTROMETRY; MOLECULAR STRUCTURE; PEPTIDE FRAGMENTS; SMALL MOLECULE LIBRARIES; STEREOISOMERISM;

EID: 84870929135     PISSN: 16182642     EISSN: 16182650     Source Type: Journal    
DOI: 10.1007/s00216-012-6335-6     Document Type: Article

References (32)

1. Sun C, Petros AM, Hajduk PJ (2011) Fragment-based lead discovery: challenges and opportunities. J Comput Aided Mol Des 25:607-610
2. Murray CW, Rees DC (2009) The rise of fragment-based drug discovery. Nat Chem 1:187-192
3. Kuo LC (2011) Fragment-based drug design: tools, practical approaches and examples. Elsevier, San Diego
4. Bembenek SD, Tounge BA, Reynolds CH (2009) Ligand efficiency and fragment-based drug discovery. Drug Discov Today 14:278-283
5. Coyne AG, Scott DE, Abell C (2010) Drugging challenging targets using fragment-based approaches. Curr Opin Chem Biol 14:299- 307
6. Jencks WP (1981) On the attribution and additivity of binding energies. Proc Natl Acad Sci USA 78:4046-4050
7. Shuker SB, Hajduk PJ, Meadows RP, Fesik SW (1996) Discovering high-affinity ligands for proteins: SAR by NMR. Science 274:1531-1534
8. Bollag G, Hirth P, Tsai J, Zhang J, Ibrahim PN, Cho H et al (2010) Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma. Nature 467:596-599
9. Giamas G, Man YL, Hirner H, Bischof J, Kramer K, Khan K et al (2010) Kinases as targets in the treatment of solid tumors. Cell Signal 22:984-1002
10. Catapano LA, Manji HK (2008) Kinases as drug targets in the treatment of bipolar disorder. Drug Discov Today 13:295-302
11. Akritopoulou-Zanze I, Hajduk PJ (2009) Kinase-targeted libraries: the design and synthesis of novel, potent, and selective kinase inhibitors. Drug Discov Today 14:291-297
12. Xiang Y, Hirth B, Asmussen G, Biemann H-P, Bishop KA, Good A et al (2011) The discovery of novel benzofuran-2-carboxylic acids as potent Pim-1 inhibitors. Bioorg Med Chem Lett 21:3050-3056
13. Hughes SJ, Millan DS, Kilty IC, Lewthwaite RA, Mathias JP, O'Reilly MA et al (2011) Fragment based discovery of a novel and selective PI3 kinase inhibitor. Bioorg Med Chem Lett 21:6586-6590
14. Erlanson DA, Arndt JW, Cancilla MT, Cao K, Elling RA, English N et al (2011) Discovery of a potent and highly selective PDK1 inhibitor via fragment-based drug discovery. Bioorg Med Chem Lett 21:3078-3083
15. Frantz S (2005) Drug discovery: playing dirty. Nature 437:942-943
16. Ghoreschi K, Laurence A, O'Shea JJ (2009) Selectivity and therapeutic inhibition of kinases: to be or not to be? Nat Immunol 10:356-360
17. Hesterkamp T, Whittaker M (2008) Fragment-based activity space: smaller is better. Curr Opin Chem Biol 12:260-268
18. Hubbard RE, Murray JB (2011) Experiences in fragment-based lead discovery. Methods Enzymol 493:509-531
19. Hoffer L, Renaud J-P, Horvath D (2011) Fragment-based drug design: computational and experimental state of the art. Comb Chem High Throughput Screen 14:500-520
20. Congreve M, Carr R, Murray C, Jhoti H (2003) A "Rule of Three" for fragment-based lead. Drug Discov Today 8:876-877
21. Larsson A, Jansson A, Aberg A, Nordlund P (2011) Efficiency of hit generation and structural characterization in fragment-based ligand discovery. Curr Opin Chem Biol 15:482-488
22. Zopf D, Ohlson S (1990) Weak-affinity chromatography. Nature 346:87-88
23. Bergström M, Liu S, Kiick KL, Ohlson S (2009) Cholera toxin inhibitors studied with high-performance liquid affinity chromatography: a robust method to evaluate receptor-ligand interactions. Chem Biol Drug Des 73:132-141
24. Engström HA, Johansson R, Koch-Schmidt P, Gregorius K, Ohlson S, Bergström M (2008) Evaluation of a glucose sensing antibody using weak affinity chromatography. Biomed Chromatogr 22:272-277
25. Haginaka J (2001) Protein-based chiral stationary phases for highperformance liquid chromatography enantioseparations. J Chromatogr A 906:253-273
26. Duong-Thi M-D, Meiby E, Bergström M, Fex T, Isaksson R, Ohlson S (2011) Weak affinity chromatography as a new approach for fragment screening in drug discovery. Anal Biochem 414:138- 146
27. Dumitriu A, Pacheco CD, Wilk JB, Strathearn KE, Latourelle JC, Goldwurm S et al (2011) Cyclin-G-associated kinase modifies α-synuclein expression levels and toxicity in Parkinson's disease: results from the GenePD Study. Hum Mol Genet 20:1478- 1487
28. Rhodes SL, Sinsheimer JS, Bordelon Y, Bronstein JM, Ritz B (2011) Replication of GWAS associations for GAK and MAPT in Parkinson's disease. Ann Hum Genet 75:195-200
29. Savitsky P, Bray J, Cooper CDO, Marsden BD, Mahajan P, Burgess-Brown NA et al (2010) High-throughput production of human proteins for crystallization: the SGC experience. J Struct Biol 172:3-13
30. Strandh M, Andersson HS, Ohlson S (2000) Weak affinity chromatography. Methods Mol Biol 147:7-23
31. Kasai K, Oda Y, Nishikata M, Ishii S (1986) Frontal affinitychromatography - theory for its application to studies on specific interactions of biomolecules. J Chromatogr 376:33-47
32. Fedorov O, Marsden B, Pogacic V, Rellos P, Müller S, Bullock AN et al (2007) A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases. Proc Natl Acad Sci USA 104:20523-20528